Raul R. Rodriguez net worth and biography

Raul Rodriguez Biography and Net Worth

Raul R. Rodriguez was appointed President and Chief Executive Officer and a member of the Board of Directors in November 2014. Until then, he had served as our President and Chief Operating Officer since May 2010. He joined us as Vice President, Business Development in April 2000, became our Senior Vice President, Business Development and Commercial Operations in December 2002 and became our Executive Vice President and Chief Operating Officer in June 2004. From 1997 to March 2000, he served as Senior Vice President, Business Development and Operations for Ontogeny, Inc. (now Curis), a biotechnology company. From 1994 to 1997, he served as the Executive Director, Business Development and Market Planning for Scios, Inc. (now J&J), a pharmaceutical company. From 1989 to 1994, Mr. Rodriguez held various positions at G.D. Searle & Company (now Pfizer), a pharmaceutical company. In these companies, Mr. Rodriguez held positions of increasing responsibility in the areas of business development and planning. After earning his bachelor’s degree from Harvard College, Mr. Rodriguez went on to earn his Master of Public Health at the University of Illinois and subsequently received his M.B.A. at the Stanford Graduate School of Business.

What is Raul R. Rodriguez's net worth?: The estimated net worth of Raul R. Rodriguez is at least $11.55 million as of February 4th, 2025. Mr. Rodriguez owns 243,854 shares of Rigel Pharmaceuticals stock worth more than $11,553,803 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Rodriguez may own. Additionally, Mr. Rodriguez receives a salary of $1,170,000.00 as CEO at Rigel Pharmaceuticals. Learn More about Raul R. Rodriguez's net worth.
How old is Raul R. Rodriguez?: Mr. Rodriguez is currently 63 years old. There are 6 older executives and no younger executives at Rigel Pharmaceuticals. Learn More on Raul R. Rodriguez's age.
What is Raul R. Rodriguez's salary?: As the CEO of Rigel Pharmaceuticals, Inc., Mr. Rodriguez earns $1,170,000.00 per year. Learn More on Raul R. Rodriguez's salary.
How do I contact Raul R. Rodriguez?: The corporate mailing address for Mr. Rodriguez and other Rigel Pharmaceuticals executives is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. Rigel Pharmaceuticals can also be reached via phone at (650) 624-1100 and via email at [email protected]. Learn More on Raul R. Rodriguez's contact information.
Has Raul R. Rodriguez been buying or selling shares of Rigel Pharmaceuticals?: Raul R. Rodriguez has not been actively trading shares of Rigel Pharmaceuticals within the last three months. Most recently, Raul R. Rodriguez sold 4,952 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a transaction totalling $103,595.84. Following the completion of the sale, the chief executive officer now directly owns 243,854 shares of the company's stock, valued at $5,101,425.68. Learn More on Raul R. Rodriguez's trading history.
Who are Rigel Pharmaceuticals' active insiders?: Rigel Pharmaceuticals' insider roster includes Raul Rodriguez (CEO), David Santos (EVP), and Dean Schorno (CFO). Learn More on Rigel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rigel Pharmaceuticals?: In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 9,113 shares worth more than $190,643.96. The most recent insider tranaction occured on February, 4th when CFO Dean L Schorno sold 2,036 shares worth more than $42,593.12. Insiders at Rigel Pharmaceuticals own 9.5% of the company. Learn More about insider trades at Rigel Pharmaceuticals.
Information on this page was last updated on 2/4/2025.

Raul R. Rodriguez Insider Trading History at Rigel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/4/2025	Sell	4,952	$20.92	$103,595.84	243,854
6/9/2022	Buy	100,000	$6.90	$690,000.00	139,177
8/17/2018	Buy	11,400	$26.30	$299,820.00

Raul R. Rodriguez Buying and Selling Activity at Rigel Pharmaceuticals

Rigel Pharmaceuticals Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Today's Range

Now: $47.38

$46.76

$48.50

50 Day Range

MA: $35.50

$26.83

$50.96

2 Week Range

Now: $47.38

$14.63

$52.24

Volume

395,257 shs

Average Volume

650,314 shs

Market Capitalization

$859.95 million

P/E Ratio

7.68

Dividend Yield

N/A

Beta

1.11

Raul Rodriguez Biography and Net Worth

What is Raul R. Rodriguez's net worth?

How old is Raul R. Rodriguez?

What is Raul R. Rodriguez's salary?

How do I contact Raul R. Rodriguez?

Has Raul R. Rodriguez been buying or selling shares of Rigel Pharmaceuticals?

Who are Rigel Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Rigel Pharmaceuticals?